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Abstract
Historically, asthma has been envisioned as a disease of younger ages. This has led to the assumption that respiratory
symptoms suggestive of asthma occurring in older ages are to be attributed to conditions other than asthma, mainly
COPD. Old observational reports and new epidemiological studies confirm that asthma is as frequent in older as it is in
younger populations. Nevertheless, under-recognition, misdiagnosis and under-treatment are still relevant issues. The
characterization of asthma in the aged suffers from the fact that there has been very little original research in this field.
Indeed, geriatric asthma is often excluded from clinical trials because of age and comorbidities. The current review
paper revises the areas that need to be elucidated, and highlights the gaps in the management of this condition. It
follows that a multidimensional management is advocated for elderly asthmatics to evaluate the severity and establish
the complexity of the disease. We suggest that the term “geriatric” asthma should be preferred to “senile” asthma,
which is confined to the age-related changes in the lung, or the more generic “asthma in the elderly”, which is only
descriptive of the prevalence in specific age groups.
Keywords: Geriatric asthma, Airflow obstruction, Lung function tests, Senile lung, Comorbidities
Background
The geriatric patient undergoes age-related structural and
physiological changes of the lung that strongly influence
the features of airway obstruction, which appears more
severe and less reversible in response to treatment. Several
studies have demonstrated that asthma in older individ-
uals is characterized by a greater reduction in lung func-
tion, with lower FEV1% predicted as opposed to younger
asthmatics. This could contribute to identify a subgroup
of severe asthmatics in whom age-related changes are
predominant. In addition to this, the acute response to
bronchodilators is usually (not always) blunted, and fea-
tures of reversibility of bronchial obstruction are therefore
less prevalent in this age range.
The occurrence of comorbid conditions in geriatric asth-
matics is the norm. Physicians are therefore forced to face
with the interaction of multiple diseases, and the success of
asthma treatment is expected to fail if the comorbidities
are not treated appropriately, or at least taken into consid-
eration in the medical decisions. The latter includes several
aspects: comorbidities can influence the absorption, distri-
bution, metabolism and excretion of anti-asthmatic drugs.
Similarly, the non-respiratory drugs can interact to a vari-
able extent with the respiratory ones, influencing their
pharmacokinetics and pharmacodynamics. If these aspects
are not properly addressed in clinical practice, the risk of
treatment failure and occurrence of systemic and local side
effects becomes relevant.
In the current review, we aim at revising the areas that
need to be further elucidated from a clinical standpoint,
and highlights the major challenges in the management
of geriatric asthma.
Lung functional issues in the diagnosis of geriatric
asthma
The persistently higher, and poorly reversible, airway
obstruction poses a challenge in the diagnosis of asthma:
the risk of misdiagnosis or underdiagnosis is around the
corner, and physicians should avoid the risk of following
false myths, such as the fact that the lack of reversibility
excludes asthma. Findings from the Sa.R.A. Study (Italian
acronym for Respiratory Health in the Elderly) showed
that only one out of two elderly subjects with carefully
ascertained asthma had received a correct diagnosis; con-
versely, the 20 % of the sample had reported an erroneous
diagnosis of COPD [1]. There are reasons why asthma in
the elderly loses its “young” characteristics: the lung par-
enchyma in the elderly undergoes an homogeneous
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enlargement of airspaces without destruction [2]. The
senile lung can be easily distinguished from the emphyse-
matous lung, where the airspace enlargement has an
irregular distribution with destruction. This has also been
demonstrated by using the lung density by computed tom-
ography [3]. Consequently, the static elastic recoil pressure
of the lung diminishes [4], causing reduction in flow rates
and vital capacity. The increased compressibility of the air-
ways with age becomes evident at low lung volumes,
where the reduction in lung elastic recoil overcomes that
of the airways, leading to airflow limitation and airway
closure. Obviously, the remodelling changes of the airways
with increased thickness of the airway wall oppose the di-
lating effect. These alterations are not susceptible to the
effects of treatment, accounting for the loss of reversibility
and the persistence of airway obstruction. The lack of
functional reversibility is likely related also to the reduced
responsiveness of airway beta2-adrenoceptors, which has
been demonstrated in healthy elderly subjects [5].
In the evaluation of the functional determinants of
asthma in the elderly, the short-term response to a course
of oral corticosteroids, or the long-term response to inhaled
corticosteroids (ICS) could be a substitute (or a surrogate)
of the acute response to short-acting bronchodilators. This
is an interesting area of research in the geriatric population.
One of the limitations (again, a false myth) is the difficulty
in obtaining an optimal lung function assessment by means
of spirometry. By no doubt, spirometry is an effort-
dependent maneuver, and the collaboration of the patient
together with the interaction between the patient and the
operator are mandatory. One is therefore led to believe that
elderly subjects, by definition, cannot perform a good-
quality spirometry. At variance with this misconception,
the Sa.R.A. study clearly demonstrated that a good quality
test can be obtained in the vast majority of elderly individ-
uals suffering from asthma, provided that the personnel is
specifically trained [6]; it was also observed that the
performance progressively improves with increasing experi-
ence. This emphasizes the opportunity to use reliable sur-
rogate for the forced vital capacity (FVC), such as the
forced expiratory volume in six seconds (FEV6), to improve
the capabilities of lung function assessment in the elderly.
Bellia et al. [7] were able to demonstrate, in a large sample
of elderly subjects, that FEV6 is more easily achievable and
more reproducible than FVC; indeed, FEV6 was obtained
in 82.9 % of spirometries with acceptable start of test, while
FVC only in 56.9 %. A good reproducibility (difference
between the best two values <5 %) was found in 88.5 % of
tests for FEV6 and in 86.1 % for FVC, whereas the corre-
sponding figures in obstructed patients were 84.3 % and
75.9 %, respectively.
Beside the issues related to the performance, the crit-
ical limitations of the spirometry in the geriatric popula-
tion are represented by the choice of suitable cut-off
diagnostic levels and the lack of appropriate reference
values. It is highly recommended that the lower limit of
normality is employed to interpret the spirometric
results in the geriatric population. There is evidence that
the fixed cut-off value of 0.70 for FEV1/FVC becomes
inaccurate in males aged >40 years and females >50 years
[8], implying the risk of an overestimation of the airway
obstruction. This has been shown particularly in asymp-
tomatic older individuals with no history of exposure to
risk factors and respiratory symptoms, in whom an age-
related decline in lung volumes is observed [9].
Since elastic recoil is considered a limiting factor for
the maximum decrease in airway caliber during
bronchoconstriction [10], the age-associated alterations
in lung properties may result in enhanced airway re-
sponse to spasmogens, which is a cardinal feature of
geriatric asthma. Airway hyperresponsiveness (AHR) is
not rare amongst the elderly, the reasons being geomet-
rical factors associated with reduced airway caliber, history
of smoke exposure and atopy [11]. The evaluation of AHR
does not add any value to the diagnostic approach in the
geriatric individual from a clinical standpoint; however,
the phenomenon of exaggerated airway closure docu-
mented in the elderly asthmatics [12], meaning a greater
reduction in FVC than in FEV1 during a bronchoprovoca-
tion challenge, implies that elderly are at higher risk of
dramatic episodes of bronchospasms, which can even be
letal in some circumstances. Whether this is worth explor-
ing in clinical settings should be decided on specific cases,
and research should aim at finding simpler surrogates for
the detection of AHR in elderly asthmatics.
Fabbri et al. [13] showed that asthma in the elderly
maintains a markedly different pathology compared to
COPD, even in the presence of non reversible airway
obstruction. In line with this, another Italian study found
that despite similar fixed airflow obstruction, elderly
patients with asthma have distinct inflammatory pattern
in induced sputum and in peripheral blood compared with
patients with COPD [14]. These observations raise the
need to search for novel biomarkers that might allow to
distinguish asthma from COPD in the geriatric ages, and
to separate asthma from the asthma-COPD overlap
syndrome.
Although the prevalence of atopy is reduced with
aging [15], atopy still plays a primary role in the most
advanced ages [16]. In other words, despite a decreased
prevalence of atopy, the severity of allergic conditions
may be increased in older age. For example, an highest
risk for asthma hospitalization when atopy and viral
infections are combined has been described [17].
Specific interventions aiming at reducing the exposure
to environmental stimuli, or specific allergy treatment
(e.g. immunotherapy or anti-IgE treatment) are candi-
date areas for specifically designed studies.
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The challenge of comorbidities in the management of
geriatric asthma
The prevalence of chronic degenerative diseases tends to
increase with age [18]; an interesting area of research is to
explore whether multiple comorbid conditions share a
common pathway; for instance, the metabolic syndrome
could be pathogenetically linked to asthma through the
pro-inflammatory low density lipoproteins, (LDL) as sug-
gested by Scichilone et al. [19] and by Barochia et al. [20].
Small LDL could lead to the amplification of the inflamma-
tory cascade in asthma: larger studies specifically designed
to confirm the association between asthma and dyslipid-
emia in the geriatric asthma are strongly needed. In a co-
hort of older individuals, Soriano et al. [21] demonstrated
an association between asthma and diseases of different
organ systems (especially cardiac), with an increased risk of
myocardial infarction and angina. Similarly, the association
between asthma and atrial fibrillation has been recently
shown [22], suggesting that asthma may initiate atrial fibril-
lation. Moreover, the current use of systemic and inhaled
corticosteroids and bronchodilators appeared to be linked
to the increased risk of atrial fibrillation in elderly individ-
uals with asthma; on the other hand, medications often
used by elderly patients, like ß-adrenergic blockers, might
elicit or worsen bronchoconstriction.
In addition to the role of comorbidities in affecting
pharmacological treatment, comorbid conditions may
impair the ability to use inhalation devices [23]; this is
the case for arthritis of hands and fingers, which causes
hand grip problems, visual or cognitive impairments that
affect the ability to properly use the inhaled device, and
changes in the state of mood (anxiety and depression)
which can severely reduce the adherence to treatment.
In this respect, it is logical to assume that comorbidities
and complex treatment regimens can negatively influ-
ence the compliance of the asthmatic patient, thus limit-
ing the efficacy of treatment in this age range. It follows
that the choice of the proper inhaler device is as import-
ant as the choice of the active drug, and should be based
on the assessment of coordination between activation
and inhalation as well as of the inspiratory flow, together
with the evaluation of visual or cognitive impairments.
Unfortunately, the progresses in technology in the devel-
opment of new devices do not seem to have incorpo-
rated the needs of the geriatric patients. It is auspicable
that specific practical advices and recommendations for
the selection of the inhaler device in geriatric asthma
would be implemented in clinical daily practice.
Conclusions
The above-described pitfalls and challenges in geriatric
asthma call for a different approach to this pathological
condition. It is now accepted that the management of
asthma in the elderly should switch from a disease-
oriented scheme to a dysfunction-oriented behaviour. In
addition to a comprehensive lung function assessment, a
multidimensional approach with a multidisciplinary inter-
vention is suggested for elderly asthmatics to evaluate the
severity and establish the complexity of the disease. For
these reasons, we suggest that the term “geriatric” asthma
should be preferred to “senile” asthma, which is confined
to the age-related changes in the lung, or the more generic
“asthma in the elderly”, which is only descriptive of the
prevalence in specific age groups. Geriatric asthma is no
longer an enigma to be solved, nor is an “orphan” disease:
on the contrary, accumulating evidence confirm that the
time has come for a specific (multidimensional) manage-
ment to be implemented in clinical practice.
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